Severe fatigue, sleep disturbance and drowsiness during oropharyngeal cancer RT were independently associated with substantially worse overall survival.
PTCOG experts recommend two CTVs covering the clivus and full preoperative tumor bed with anatomy-adapted margins after surgery.
Normal-lung CT response was partly reproducible across RT courses, while short retreatment intervals increased response in previously irradiated lung.
Memantine preserved 6-month cognition versus placebo after radiotherapy for brain metastases, with benefits also seen in quality of life.
In 752 NPC patients, 45-Gy EQD2 elective nodal irradiation achieved 97.3% 5-year regional control with only 0.7% elective-volume failures.
ROAM/EORTC-1308 improved 5-year disease-free survival from 64.3% to 79.9% after complete resection of WHO grade 2 meningioma.
All 15 replans met target coverage, but one-third exceeded at least one bowel objective and kidney constraints remained challenging.
Nationwide referral to one MR-IGABT centre kept median treatment time at 50 days and achieved 95% 3-year local control.
Grade ≥2 GI toxicity was 14% with oART versus 45% with IGRT, with better preservation of several HRQoL domains.
PET/CT reduced mean PTV by 149 cm³ while identifying substantial disease outside CT-based targets in 20% of patients.
A 28-fraction SIB course shortened postoperative soft tissue sarcoma radiotherapy by about one week, with no significant matched outcome or toxicity differences.
One patient underwent 21 Gy in three fractions to 44 recurrent brain metastases after WBRT, with rapid delivery and sustained local control.
Across 32 years of T1 anal cancer treatment, five-year colostomy-free survival reached 85.3%, with no treatment-related colostomies.
Postoperative bowel dysfunction correlated most strongly with high-dose exposure to the internal anal sphincter and puborectalis complex.
Central thoracic re-irradiation achieved 80.1% one-year local control, while cumulative esophageal V60 emerged as a potential toxicity signal.